vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and LCNB CORP (LCNB). Click either name above to swap in a different company.
LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $16.1M, roughly 1.5× Journey Medical Corp). LCNB CORP runs the higher net margin — 23.7% vs -7.8%, a 31.5% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 5.1%). Over the past eight quarters, LCNB CORP's revenue compounded faster (15.7% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.
DERM vs LCNB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $23.9M |
| Net Profit | $-1.2M | $5.7M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 29.2% |
| Net Margin | -7.8% | 23.7% |
| Revenue YoY | 27.3% | 5.1% |
| Net Profit YoY | -182.0% | -7.6% |
| EPS (diluted) | $-0.04 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $23.9M | ||
| Q3 25 | $17.0M | $23.8M | ||
| Q2 25 | $15.0M | $22.8M | ||
| Q1 25 | $13.1M | $21.5M | ||
| Q4 24 | $12.6M | $22.7M | ||
| Q3 24 | $14.6M | $21.4M | ||
| Q2 24 | $14.9M | $19.3M | ||
| Q1 24 | $13.0M | $17.8M |
| Q4 25 | $-1.2M | $5.7M | ||
| Q3 25 | $-2.3M | $6.9M | ||
| Q2 25 | $-3.8M | $5.9M | ||
| Q1 25 | $-4.1M | $4.6M | ||
| Q4 24 | $1.5M | $6.1M | ||
| Q3 24 | $-2.4M | $4.5M | ||
| Q2 24 | $-3.4M | $925.0K | ||
| Q1 24 | $-10.4M | $1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | 29.2% | ||
| Q3 25 | -9.0% | 35.6% | ||
| Q2 25 | -19.2% | 31.6% | ||
| Q1 25 | -25.3% | 25.6% | ||
| Q4 24 | 17.7% | 32.9% | ||
| Q3 24 | -19.8% | 24.9% | ||
| Q2 24 | -19.7% | 4.9% | ||
| Q1 24 | -77.4% | 12.5% |
| Q4 25 | -7.8% | 23.7% | ||
| Q3 25 | -13.6% | 29.1% | ||
| Q2 25 | -25.3% | 26.0% | ||
| Q1 25 | -31.0% | 21.4% | ||
| Q4 24 | 12.1% | 27.0% | ||
| Q3 24 | -16.3% | 21.2% | ||
| Q2 24 | -22.6% | 4.8% | ||
| Q1 24 | -80.1% | 10.7% |
| Q4 25 | $-0.04 | $0.40 | ||
| Q3 25 | $-0.09 | $0.49 | ||
| Q2 25 | $-0.16 | $0.41 | ||
| Q1 25 | $-0.18 | $0.33 | ||
| Q4 24 | $0.10 | $0.44 | ||
| Q3 24 | $-0.12 | $0.31 | ||
| Q2 24 | $-0.17 | $0.07 | ||
| Q1 24 | $-0.53 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $21.6M |
| Total DebtLower is stronger | $25.3M | $104.4M |
| Stockholders' EquityBook value | $31.9M | $273.9M |
| Total Assets | $94.6M | $2.2B |
| Debt / EquityLower = less leverage | 0.79× | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $21.6M | ||
| Q3 25 | $24.9M | $35.9M | ||
| Q2 25 | $20.3M | $49.8M | ||
| Q1 25 | $21.1M | $37.7M | ||
| Q4 24 | $20.3M | $35.7M | ||
| Q3 24 | $22.5M | $39.4M | ||
| Q2 24 | $23.9M | $34.9M | ||
| Q1 24 | $24.1M | $33.0M |
| Q4 25 | $25.3M | $104.4M | ||
| Q3 25 | $25.2M | $104.7M | ||
| Q2 25 | $25.1M | $105.0M | ||
| Q1 25 | $25.0M | $104.6M | ||
| Q4 24 | $24.9M | $155.2M | ||
| Q3 24 | $19.8M | $155.7M | ||
| Q2 24 | $19.7M | $162.2M | ||
| Q1 24 | $14.7M | $162.6M |
| Q4 25 | $31.9M | $273.9M | ||
| Q3 25 | $25.9M | $269.9M | ||
| Q2 25 | $19.2M | $263.5M | ||
| Q1 25 | $21.5M | $258.7M | ||
| Q4 24 | $20.1M | $253.0M | ||
| Q3 24 | $10.9M | $253.2M | ||
| Q2 24 | $11.3M | $245.2M | ||
| Q1 24 | $13.0M | $233.7M |
| Q4 25 | $94.6M | $2.2B | ||
| Q3 25 | $85.2M | $2.2B | ||
| Q2 25 | $81.2M | $2.3B | ||
| Q1 25 | $85.0M | $2.3B | ||
| Q4 24 | $80.2M | $2.3B | ||
| Q3 24 | $64.0M | $2.3B | ||
| Q2 24 | $65.2M | $2.4B | ||
| Q1 24 | $66.6M | $2.3B |
| Q4 25 | 0.79× | 0.38× | ||
| Q3 25 | 0.97× | 0.39× | ||
| Q2 25 | 1.30× | 0.40× | ||
| Q1 25 | 1.16× | 0.40× | ||
| Q4 24 | 1.24× | 0.61× | ||
| Q3 24 | 1.81× | 0.61× | ||
| Q2 24 | 1.75× | 0.66× | ||
| Q1 24 | 1.13× | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $34.4M |
| Free Cash FlowOCF − Capex | — | $33.4M |
| FCF MarginFCF / Revenue | — | 140.2% |
| Capex IntensityCapex / Revenue | — | 4.0% |
| Cash ConversionOCF / Net Profit | — | 6.08× |
| TTM Free Cash FlowTrailing 4 quarters | — | $54.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $34.4M | ||
| Q3 25 | $-2.4M | $14.0M | ||
| Q2 25 | $-942.0K | $5.5M | ||
| Q1 25 | $-2.8M | $2.2M | ||
| Q4 24 | $2.2M | $93.2M | ||
| Q3 24 | $-1.2M | $11.9M | ||
| Q2 24 | $-5.2M | $54.9M | ||
| Q1 24 | $-5.0M | $-11.9M |
| Q4 25 | — | $33.4M | ||
| Q3 25 | — | $13.7M | ||
| Q2 25 | — | $5.2M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $89.4M | ||
| Q3 24 | — | $10.5M | ||
| Q2 24 | — | $53.8M | ||
| Q1 24 | — | $-12.8M |
| Q4 25 | — | 140.2% | ||
| Q3 25 | — | 57.4% | ||
| Q2 25 | — | 23.0% | ||
| Q1 25 | — | 10.0% | ||
| Q4 24 | — | 394.0% | ||
| Q3 24 | — | 49.0% | ||
| Q2 24 | — | 278.6% | ||
| Q1 24 | — | -71.8% |
| Q4 25 | — | 4.0% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 16.7% | ||
| Q3 24 | — | 6.7% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 4.8% |
| Q4 25 | — | 6.08× | ||
| Q3 25 | — | 2.02× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | 1.46× | 15.23× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | — | 59.35× | ||
| Q1 24 | — | -6.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
LCNB
Segment breakdown not available.
